Cargando…

Preclinical Pharmacokinetics of Complement C5a Receptor Antagonists PMX53 and PMX205 in Mice

[Image: see text] The cyclic hexapeptides PMX53 and PMX205 are potent noncompetitive inhibitors of complement C5a receptor 1 (C5aR1). They are widely utilized to study the role of C5aR1 in mouse models, including central nervous system (CNS) disease, and are dosed through a variety of routes of admi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kumar, Vinod, Lee, John D., Clark, Richard J., Noakes, Peter G., Taylor, Stephen M., Woodruff, Trent M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2020
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017397/ https://www.ncbi.nlm.nih.gov/pubmed/32064396 http://dx.doi.org/10.1021/acsomega.9b03735

Ejemplares similares

Development and validation of a LC-MS/MS assay for pharmacokinetic studies of complement C5a receptor antagonists PMX53 and PMX205 in mice
por: Kumar, Vinod, et al.
Publicado: (2018)

Insights into the mechanism of C5aR inhibition by PMX53 via implicit solvent molecular dynamics simulations and docking
por: Tamamis, Phanourios, et al.
Publicado: (2014)

Is it true that PMX-DHP can improve lung oxygenation?
por: Ikeda, T, et al.
Publicado: (2003)

Effect of PMX-DHP according to differences in infection site
por: Ikeda, T, et al.
Publicado: (2001)

Observational study for direct hemoperfusion therapy with polymyxin-B immobilized fibers (PMX-DHP) in patients with septic shock in Japan: PMX-DHP study group
por: Kase, Y, et al.
Publicado: (2009)

pmx: Automated protein structure and topology generation for alchemical perturbations
por: Gapsys, Vytautas, et al.
Publicado: (2015)

ACTH and PMX53 recover synaptic transcriptome alterations in a rat model of infantile spasms
por: Iacobaş, Dumitru A., et al.
Publicado: (2018)

Tocilizumab and PMX-DHP have efficacy for severe COVID-19 pneumonia
por: Shinomiya, Shohei, et al.
Publicado: (2021)

A retrospective investigation of the pmx-dhp's efficacy in 88 severe sepsis cases
por: Tanaka, M, et al.
Publicado: (2015)

Efficacy of the endotoxin absorption method (PMX) in patients with septic shock associated with intraperitoneal infections
por: Ikeda, T, et al.
Publicado: (2000)

Therapeutic Rationale for Endotoxin Removal with Polymyxin B Immobilized Fiber Column (PMX) for Septic Shock
por: Shoji, Hisataka, et al.
Publicado: (2021)

Antitumor Quinol PMX464 Is a Cytocidal Anti-trypanosomal Inhibitor Targeting Trypanothione Metabolism
por: König, Janine, et al.
Publicado: (2011)

PMX-DHP Therapy for Dyspnea and Deoxygenation in Severe COVID-19 Pneumonia: A Case Series
por: Kuwana, Tsukasa, et al.
Publicado: (2021)

Clinical evaluation of endotoxin hemoadsorption therapy (PMX-DHP) for hypercytokinemia caused by septic multiple organ failure
por: Ikeda, T, et al.
Publicado: (2004)

Quantum Mechanical Calculation of Noncovalent Interactions: A Large-Scale Evaluation of PMx, DFT, and SAPT Approaches
por: Li, Amanda, et al.
Publicado: (2014)

ABL1 kinase as a tumor suppressor in AML1-ETO and NUP98-PMX1 leukemias
por: Golovine, Konstantin, et al.
Publicado: (2023)

Pan-peritonitis due to intestinal perforation, and efficacy of direct hemoperfusion with polymyxin B immobilized fiber (PMX-20R)
por: Ikeda, T
Publicado: (1999)

The role of plasminogen activator inhibitor 1 measurement with endotoxin adsorption therapy (PMX-DHP) for postoperative septic shock patients
por: Ikeda, T, et al.
Publicado: (2007)

First case report of a NUP98-PMX1 rearrangement in de novo acute myeloid leukemia and literature review
por: Fu, Weijia, et al.
Publicado: (2021)

The Characteristics of Patients with Severe COVID-19 Pneumonia Treated with Direct Hemoperfusion Using Polymyxin B-Immobilized Fiber Column (PMX-DHP)
por: Kuwana, Tsukasa, et al.
Publicado: (2022)

PMX464, a thiol-reactive quinol and putative thioredoxin inhibitor, inhibits NF-κB-dependent proinflammatory activation of alveolar epithelial cells
por: Callister, M E, et al.
Publicado: (2008)

Efficacy of direct hemoperfusion using polymyxin B-immobilized fiber column (PMX-DHP) in rapidly progressive interstitial pneumonias: results of a historical control study and a review of previous studies
por: Ichiyasu, Hidenori, et al.
Publicado: (2017)

Dysregulation of the complement cascade in the hSOD1(G93A) transgenic mouse model of amyotrophic lateral sclerosis
por: Lee, John D, et al.
Publicado: (2013)

The “C3aR Antagonist” SB290157 is a Partial C5aR2 Agonist
por: Li, Xaria X., et al.
Publicado: (2021)

Complement components are upregulated and correlate with disease progression in the TDP-43(Q331K) mouse model of amyotrophic lateral sclerosis
por: Lee, John D., et al.
Publicado: (2018)

Complement C5a-C5aR1 signalling drives skeletal muscle macrophage recruitment in the hSOD1(G93A) mouse model of amyotrophic lateral sclerosis
por: Wang, Haitao A., et al.
Publicado: (2017)

Complement activation in the injured central nervous system: another dual-edged sword?
por: Brennan, Faith H, et al.
Publicado: (2012)

Chemical synthesis and characterisation of the complement C5 inhibitory peptide zilucoplan
por: Gorman, Declan M., et al.
Publicado: (2021)

Editorial: The Role of Complement in Tumors
por: Rolfe, Barbara E., et al.
Publicado: (2020)

The PGRMC1 Antagonist AG-205 Inhibits Synthesis of Galactosylceramide and Sulfatide
por: Wang-Eckhardt, Lihua, et al.
Publicado: (2021)

The complement cascade in the regulation of neuroinflammation, nociceptive sensitization, and pain
por: Warwick, Charles A., et al.
Publicado: (2021)

The Complement C5a-C5aR1 GPCR Axis in COVID-19 Therapeutics
por: Woodruff, Trent M., et al.
Publicado: (2020)

Complement Component 5 (C5) Deficiency Improves Cognitive Outcome After Traumatic Brain Injury and Enhances Treatment Effects of Complement Inhibitors C1-Inh and CR2-Crry in a Mouse Model
por: Chen, Min, et al.
Publicado: (2023)

OCE-205 in rats and non-human primates: Pharmacokinetic and pharmacodynamic analysis
por: Bukofzer, Stan, et al.
Publicado: (2023)

Preclinical studies on the toxicology, pharmacokinetics and safety of K1-70(TM) a human monoclonal autoantibody to the TSH receptor with TSH antagonist activity
por: Furmaniak, Jadwiga, et al.
Publicado: (2019)

OCE-205, A Novel, Selective Vasopressin Receptor Mixed Agonist-Antagonist: Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics from a Phase 1 Study in Healthy Volunteers
por: Bagger, Yu, et al.
Publicado: (2023)

Developmental activities of the complement pathway in migrating neurons
por: Gorelik, Anna, et al.
Publicado: (2017)

Commentary: Beyond C4: Analysis of the complement gene pathway shows enrichment for IQ in patients with psychotic disorders and healthy controls
por: Coulthard, Liam G., et al.
Publicado: (2019)

Preclinical pharmacokinetics of benznidazole.
por: Workman, P., et al.
Publicado: (1984)

Valproic acid attenuates cellular senescence in diabetic kidney disease through the inhibition of complement C5a receptors
por: Coughlan, Melinda T., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_e0cnj39bglk1utv5gjlhdoa6kd